Overview

A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the pancreas.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Insulin
Vildagliptin